Do Analysts Agree Friday on Sensei Biotherapeutics Inc (SNSE) Stock's Target Price?

Friday, August 12, 2022 03:50 PM | InvestorsObserver Analysts

Mentioned in this article

Wall Street is positive on Sensei Biotherapeutics Inc (SNSE). On average, analysts give the stock a Buy rating. The average price target is $4, which means analysts expect the stock to add by 81.82% over the next twelve months. That average ranking earns the stock an Analyst Rating of 32, which is better than 32% of stocks based on data compiled by InvestorsObserver.

Wall Street analysts are rating SNSE a Buy today. Find out what this means to you and get the rest of the rankings on SNSE!
See Full SNSE Report

Why are Analyst Ratings Important?

A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement. InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.

What's Happening With Sensei Biotherapeutics Inc Stock Today?

Sensei Biotherapeutics Inc (SNSE) stock is trading at $2.20 as of 3:49 PM on Friday, Aug 12, an increase of $0.06, or 2.81% from the previous closing price of $2.14. The stock has traded between $2.14 and $2.28 so far today. Volume today is 45,300 compared to average volume of 38,105. Click Here to get the full Stock Report for Sensei Biotherapeutics Inc stock.

Share this article:

Related Articles